Cystatin C in Acute Heart Failure Without Advanced Renal Impairment

被引:75
|
作者
Naruse, Hiroyuki [2 ]
Ishii, Junnichi [1 ]
Kawai, Tomoko [2 ]
Hattori, Kousuke [2 ]
Ishikawa, Makoto [2 ]
Okumura, Masanori [2 ]
Kan, Shino [2 ]
Nakano, Tadashi [2 ]
Matsui, Shigeru [2 ]
Nomura, Masanori [2 ]
Hishida, Hitoshi [2 ]
Ozaki, Yukio [2 ]
机构
[1] Fujita Hlth Univ, Sch Med, Dept Joint Res Lab Clin Med, Toyoake, Aichi 4701192, Japan
[2] Fujita Hlth Univ, Sch Med, Dept Internal Med, Toyoake, Aichi 4701192, Japan
关键词
Acute heart failure; Creatinine; Cystatin C; Glomerular filtration rate; MDRD; Prognosis; Renal impairment; VENTRICULAR EJECTION FRACTION; PRESERVED SYSTOLIC FUNCTION; GLOMERULAR-FILTRATION-RATE; SERUM CREATININE; KIDNEY-FUNCTION; CARDIOVASCULAR OUTCOMES; RISK-FACTOR; DYSFUNCTION; DISEASE; MARKER;
D O I
10.1016/j.amjmed.2008.10.042
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The prognostic value of cystatin C relative to glomerular filtration rate (GFR) estimated by the Modification of Diet in Renal Disease Study (MDRD) equation modified for Japan has not been investigated in acute heart failure patients with normal to moderately impaired renal function. More accurate detection of mild renal impairment might improve the risk stratification of heart failure patients, especially patients with normal to moderately impaired renal function. METHODS: Cystatin C and creatinine levels were measured on admission in 328 consecutive patients hospitalized for worsening chronic heart failure with a GFR estimated by MDRD equation modified for Japan >= 30 mL/min/1.73 m(2). RESULTS: During a median follow-up period of 915 days, there were 52 (16%) cardiac deaths. In stepwise Cox regression analyses including cystatin C and GFR estimated by MDRD equation modified for Japan (either as continuous variables or as variables categorized into quartiles), cystatin C (P <.0001), but not GFR estimated by MDRD equation modified for Japan, was independently associated with cardiac mortality. Adjusted relative risk according to the quartiles of these markers and Kaplan-Meier analyses revealed that the cystatin C was a better marker to separate low-risk from high-risk patients. Furthermore, receiver-operating characteristic curve analyses of these markers revealed that cystatin C showed a higher precision in predicting cardiac mortality. CONCLUSION: Measurements of cystatin C might improve early risk stratification compared with GFR estimated by MDRD equation modified for Japan in acute heart failure patients with normal to moderately impaired renal function. (C) 2009 Elsevier Inc. All rights reserved. (C) The American Journal of Medicine (2009) 122, 566-573
引用
收藏
页码:566 / 573
页数:8
相关论文
共 50 条
  • [31] Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP
    Lassus, Johan
    Harjola, Veli-Pekka
    Sund, Reijo
    Siirilae-Waris, Krista
    Melin, John
    Peuhkurinen, Keijo
    Pulkki, Kari
    Nieminen, Markku S.
    EUROPEAN HEART JOURNAL, 2007, 28 (15) : 1841 - 1847
  • [32] The impact of admission cystatin C levels on in-hospital and three-year mortality rates in acute decompensated heart failure
    Selcuk, Hatice
    Selcuk, Mehmet Timur
    Maden, Orhan
    Balci, Kevser Gulcihan
    Balci, Mustafa Mucahit
    Tekeli, Sebahat
    Cetin, Elif Hande
    Temizhan, Ahmet
    Balci, Mustafa
    Karabiber, Nihal
    CARDIOVASCULAR JOURNAL OF AFRICA, 2018, 29 (05) : 305 - 309
  • [33] Cystatin C and eGFRCKD-EPI-CysC: novel biomarkers for renal impairment diagnosis and two-year progression-free survival in multiple myeloma
    Niu, Jian
    Yu, Jiajia
    Huang, Huifang
    Shi, Jinfang
    Zheng, Dong
    Qiu, Jun
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2023, 83 (08) : 599 - 603
  • [34] Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function: Results From the ASCEND-HF Trial
    Tang, W. H. Wilson
    Dupont, Matthias
    Hernandez, Adrian F.
    Voors, Adriaan A.
    Hsu, Amy P.
    Felker, G. Michael
    Butler, Javed
    Metra, Marco
    Anker, Stefan D.
    Troughton, Richard W.
    Gottlieb, Stephen S.
    McMurray, John J.
    Armstrong, Paul W.
    Massie, Barry M.
    Califf, Robert M.
    O'Connor, Christopher M.
    Starling, Randall C.
    JACC-HEART FAILURE, 2015, 3 (01) : 40 - 49
  • [35] Subtle change of cystatin C, with or without acute kidney injury, associated with increased mortality in the intensive care unit
    Kwon, Soon Hyo
    Hyun, Jinnam
    Jeon, Jin Seok
    Noh, Hyunjin
    Han, Dong Cheol
    JOURNAL OF CRITICAL CARE, 2011, 26 (06) : 566 - 571
  • [36] Utility of cystatin C for renal function in amyotrophic lateral sclerosis
    Tetsuka, S.
    Morita, M.
    Ikeguchi, K.
    Nakano, I.
    ACTA NEUROLOGICA SCANDINAVICA, 2013, 128 (06): : 386 - 390
  • [37] Plasma Cystatin C Is a Predictor of Renal Dysfunction, Acute-on-Chronic Liver Failure, and Mortality in Patients With Acutely Decompensated Liver Cirrhosis
    Markwardt, Daniel
    Holdt, Lesca
    Steib, Christian
    Benesic, Andreas
    Bendtsen, Flemming
    Bernardi, Mauro
    Moreau, Richard
    Teupser, Daniel
    Wendon, Julia
    Nevens, Frederik
    Trebicka, Jonel
    Garcia, Elisabet
    Pavesi, Marco
    Arroyo, Vicente
    Gerbes, Alexander L.
    HEPATOLOGY, 2017, 66 (04) : 1232 - 1241
  • [38] Serum cystatin C assay for the detection of early renal impairment in diabetic patients
    Xia, LH
    Bing, XG
    An, XT
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2004, 18 (01) : 31 - 35
  • [39] Comparison of cystatin C versus creatinine for detection of mild renal failure
    Chantrel, F
    Agin, A
    Offner, M
    Koehl, C
    Moulin, B
    Hannedouche, T
    CLINICAL NEPHROLOGY, 2000, 54 (05) : 374 - 381
  • [40] Cystatin C and α-1-Microglobulin Predict Severe Acute Kidney Injury in Patients with Hemorrhagic Fever with Renal Syndrome
    Hansson, Magnus
    Gustafsson, Rasmus
    Jacquet, Chloe
    Chebaane, Nedia
    Satchell, Simon
    Thunberg, Therese
    Ahlm, Clas
    Connolly, Anne-Marie Fors
    PATHOGENS, 2020, 9 (08): : 1 - 14